Why did RGEN's Q3 2024 EPS exceed forecasts?

Repligen's Q3 2024 EPS exceeded forecasts due to a combination of factors:

1. **Protein Franchise Performance**: The protein franchise is expected to deliver $67-$72 million in revenues for the year 2024. This indicates a strong contribution to the company's overall earnings.
2. **New Modalities Business**: The company's new modalities business, which includes cell and gene therapy, is likely to have picked up pace in generating revenues. This segment has the potential to deliver additional earnings beyond the protein franchise.
3. **Financial Adjustments**: The company's financial adjustments, which are not recurring items, may have had a positive impact on the diluted EPS. It is important to note that the EPS Surprise was $0.1, which suggests that the company's actual EPS was $0.1 higher than the forecast.

In summary, Repligen's Q3 2024 EPS exceeded forecasts due to strong performance across its protein franchise and new modalities business, along with favorable financial adjustments.

|code|Ticker|Name|Date|Revenue Surprise|EPS Surprise|market_code|
|---|---|---|---|---|---|---|
|RGEN|RGEN.O|Repligen|2023 Q4|356636|0|185|
|RGEN|RGEN.O|Repligen|2024 Q1|1240000|-0.02|185|
|RGEN|RGEN.O|Repligen|2024 Q2|-110000|0|185|
|RGEN|RGEN.O|Repligen|2024 Q3|1780000|0.1|185|